Effect of dichoptic video game treatment on mild amblyopia – a pilot study

Peter C. K. Pang,1 Carly S. Y. Lam,1,4 Robert F. Hess2 and Benjamin Thompson3,4

1School of Optometry, The Hong Kong Polytechnic University, Kowloon, Hong Kong
2Department of Ophthalmology and Visual Sciences, McGill University, Montreal, Quebec, Canada
3School of Optometry and Vision Science, University of Waterloo, Waterloo, Ontario, Canada
4Centre for Eye and Vision Research (CEVR), Hong Kong,

ABSTRACT. Purpose: The effect of contrast-balanced dichoptic video game training on distance visual acuity (DVA) and stereo acuity has been investigated in severe-to-moderate amblyopia, but its effect on mild amblyopia and fixation stability has not been assessed. This pilot study aimed to evaluate the effect of home-based dichoptic video game on amblyopic eye DVA, stereo acuity and fixation stability in adults with mild amblyopia.

Methods: A randomized single-masked design was adopted. The active 6-week home-based treatment was an anaglyphic, contrast-balanced dichoptic video game, and the placebo was an identical non-dichoptic game. Participants (n = 23) had mild amblyopia (amblyopic DVA ≤ 0.28 log Minimum Angle of Resolution (logMAR)). The primary outcome was change in amblyopic DVA at 6 weeks postrandomization. Near visual acuity, stereo acuity and fixation stability (bivariate contour eclipse area) were also measured. Follow-up occurred at 12 and 24 weeks postrandomization.

Results: Mean amblyopic eye DVA was 0.21 ± 0.06 and 0.18 ± 0.06 logMAR for the active (n = 12) and placebo (n = 11) group, respectively. Amblyopic DVA improved significantly more in the active group (0.09 ± 0.05) than in the placebo group (0.03 ± 0.04 logMAR; p < 0.05). The difference between groups remained at 12 weeks postrandomization (p = 0.04) but not at 24 weeks (p = 0.43). Titmus stereo acuities improved significantly more in the active group (0.40 log arcsec) than in the placebo group (0.09 log arcsec) after 6 weeks of gameplay. The between-group difference was still present at 24 weeks postrandomization (p = 0.05). There were no differences between groups on any other secondary outcomes.

Conclusion: Home-based dichoptic video gameplay may be an effective method to improve amblyopic DVA and stereo acuity in mild amblyopia.

Key words: amblyopia – dichoptic video game – fixation stability – home-based treatment

Introduction

Amblyopia is a unilateral or infrequently bilateral neurodevelopmental condition that involves reduced distance visual acuity (DVA) in a healthy eye along with the presence of an amblyogenic factor such as anisometropia, strabismus or stimulus deprivation (Rouse et al. 1994). Amblyopia can be treated using optical correction (Stewart et al. 2004; Pediatric Eye Disease Investigator Group (PEDIG) et al. 2005; PEDIG et al. 2006; Chen et al. 2007; Chang et al. 2012; Gao et al. 2018a); patching or occlusion therapy (PEDIG et al. 2003; Agervi et al. 2013; Tang et al. 2014; Su et al. 2016); and atropine penalization of the nonamblyopic eye (PEDIG et al. 2015). In recent years, a number of additional treatment approaches have been developed including monocular (Levi & Li 2009) and binocular (Hess et al. 2014; Hess & Thompson 2015) perceptual learning.

Binocular perceptual learning approaches, often referred to as binocular or dichoptic treatment, involve splitting visual stimulus elements between the eyes. Amblyopic eye elements are presented at a high contrast and nonamblyopic eye elements at a lower contrast to overcome interocular suppression (Li et al. 2013a) and enable simultaneous perception. Simultaneous perception is crucial because neither eye receives all information necessary to complete the training task. Binocular treatment can be delivered in the form of modified dichoptic video games viewed through lenticular screens on tablet computers (To et al. 2011), virtual reality devices (Knox et al. 2012; Li et al. 2013b; Vedamurthy et al. 2016), shutter glasses (Herbison et al. 2016) or anaglyphic glasses (Hess
et al. 2012; Birch et al. 2015; Holmes et al. 2016; Kelly et al. 2016; Gao et al. 2018b).

Improvements in amblyopic eye visual acuity and stereopsis have been reported following binocular treatment in both adults (Hess et al. 2010; Vedamurthy et al. 2015) and children (Birch et al. 2015; Holmes et al. 2016; Kelly et al. 2016) with amblyopia. However, recent clinical trials have reported no effect of binocular treatment in older children and adults with amblyopia (Manh et al. 2018; Gao et al. 2018b; PEDIG et al. 2019). These results may have been due, in part, to difficulties in translating the treatment to the home environment (Holmes 2018; Thompson 2019).

Well-controlled binocular treatment studies have involved participants with moderate-to-severe amblyopia and distance amblyopic eye visual acuity of 0.3 logMAR or worse (Holmes et al. 2016; Kelly et al. 2016; Gao et al. 2018b; PEDIG et al. 2019). However, current amblyopia treatments rarely equate visual acuity between the two eyes in the long term, leaving patients with mild residual amblyopia (Holmes et al. 2007). The effectiveness of binocular treatment in participants with mild amblyopia (interocular DVA difference of at least 0.2 logMAR, but amblyopic eye visual acuity better than 0.3 logMAR) has not been studied.

In addition, outcome measures in binocular treatment studies have primarily focused on visual acuity, stereopsis and interocular suppression (Hess et al. 2010; Hessel et al. 2011; To et al. 2011; Hess et al. 2012; Knox et al. 2012; Li et al. 2013a; Birch et al. 2015; Li et al. 2015; Vedamurthy et al. 2015; Manh et al. 2018; Gao et al. 2018b; PEDIG et al. 2019). However, amblyopia has effects that extend beyond visual acuity and binocular vision deficits. One example is impaired fixation stability in the amblyopic eye (Ciuffreda et al. 1979; Gonzalez et al. 2012; Subramanian et al. 2013; Raveendran et al. 2014; Chung et al. 2015; Raveendran et al. 2019). Poorer amblyopic eye fixation stability is associated with poorer visual acuity (Subramanian et al. 2013; Chung et al. 2015) but does not appear to be caused by the visual acuity loss itself (Raveendran et al. 2019). It is unknown whether amblyopic eye fixation stability impairments respond to treatment.

This aim of this pilot study was to assess whether binocular treatment in the form of home-based dichoptic video gameplay was more effective than a placebo game for improving amblyopic eye DVA in a small group of individuals with mild amblyopia. Secondary outcome measures included near visual acuity (NVA), stereo acuity and fixation stability (bivariate contour ellipse area; BCEA).

Materials and Methods

Study design and sample size calculation

Based on an amblyopic eye VA improvement of 0.11 ± 0.08 (effect size = 1.38) after 6 weeks of dichoptic video game treatment (To et al., 2011) and the assumption of no VA change in the placebo group, eight participants per group would provide 90% power to detect a between-group difference in VA improvement at p < 0.05 with four repeated measurements. Allowing for dropout, 12 participants were recruited in each group.

Block randomization was employed in this study. The first 12 participants were assigned to 6 weeks of home-based treatment using an active dichoptic video game presented on a handheld iPod touch (Apple, Inc, Cupertino, California, USA) device, and the second 12 were given a placebo video game presented using the same device. Participants were followed up 6 weeks (immediately post-treatment), 12 and 24 weeks postrandomization. The primary outcome was the change in amblyopic eye DVA at 6 weeks postrandomization.

The study was conducted in parallel with the Binocular Treatment of Amblyopia with Videogames (BRAVO) randomized clinical trial (Gao et al. 2018b) and conformed to the BRAVO study protocol (Guo et al. 2016) with a number of exceptions, some of which related to the smaller scale of this study; there was only one site (The School of Optometry at Hong Kong Polytechnic University), a single-masked block randomization study design was adopted, fixation stability was assessed as an additional secondary outcome measure, and the visual acuity inclusion criteria were modified to target mild amblyopia.

The study complied with the tenets of the Declaration of Helsinki, and human ethics approvals were obtained from the Hong Kong Polytechnic University Human Ethics Committee. The study was registered at ClinicalTrials.gov (registration number: NCT02995174). Participants and their guardian (if the participants were younger than 18 years of age) provided informed written consent.

Statistical analysis

An intent-to-treat analysis was conducted. The primary outcome of change in amblyopic eye DVA from baseline to immediately post-treatment was analysed using an ANCOVA with a factor of treatment group (active versus placebo) and covariates of baseline amblyopic eye DVA, age, optical treatment history and patching history. A linear regression model was used to determine the association between the change in amblyopic eye DVA and baseline amblyopic eye DVA, age, training hours, optical treatment history and patching history. The longevity of any statistically significant treatment effects was analysed using the same ANCOVA model conducted separately on the change from baseline at each follow-up visit. The same analysis approach was applied to each secondary outcome measure. SPSS version 23 (IBM: Armonk, New York, USA) software was used to conduct the analysis.

Participants

Inclusion criteria

1. Aged 7 years or above.
2. Distance visual acuity (DVA) in amblyopic eye equal to or less than 0.28 logMAR, with an interocular difference of at least 0.20 logMAR.
3. Amblyopia could be strabismic, anisometropic or mixed (both strabismic and anisometropic). Strabismic amblyopia was defined as amblyopia in the presence of heterotropia at distance and/or near fixation. Anisometropic amblyopia was defined as amblyopia in the presence of a spherical equivalent (SE) difference ≥0.50 D between the eyes, or a difference of astigmatism in any meridian ≥1.50 D and no strabismus (Guo et al. 2016). Mixed strabismic–anisometropic amblyopia was defined as amblyopia in the presence of both strabismus and anisometropia;
4. Able to complete three successful 30-second fixation stability measurements with a MP-1 micro-perimeter for each eye.
5. Able to align the nonius cross (≤10 mm horizontal error and 5 mm vertical error) in the iPod game (the dichoptic game images could only be displaced by a limited amount to facilitate binocular alignment due to the small iPod screen size (Guo et al. 2016); and 6. Stable visual acuity with full refractive correction (Guo et al. 2016).

Exclusion criteria
1. Myopia of SE power equal to or more negative than −6.00 D in either eye.
2. Previous intraocular surgery.
3. Ocular pathology (e.g., media opacities or retinal lesions) other than strabismus.
4. Previous or current history of a neurological problem.

Baseline and outcome assessments were performed by a registered optometrist (author PP). If a participant required a change to their habitual refractive correction to meet study refractive correction criteria (Guo et al. 2016), a new correction was provided and participants were followed up at 4-week intervals until amblyopic eye DVA was stable (≤0.10 logMAR change between visits). The baseline assessment was conducted once DVA was stable.

Patching history was estimated using self-reported information from participants. Optical correction history was the number of years that the participant had been wearing optical correction prior to the baseline assessment.

Distance visual acuity (DVA) was measured using an Electronic Early Treatment Diabetic Retinopathy Study (ETDRS) test delivered on an Electronic Visual Acuity Tester system (Jaeb Center for Health Research) at 3 m (Beck et al. 2003; Cotter et al. 2003). Near visual acuity (NVA) was measured at 40 cm using the Lighthouse NVA Chart. All visual acuities were recorded using the logMAR format. Stereo acuity was measured using the Titmus stereo test and the Randot stereo test (Jaeb Center for Health Research) at 3 m (Beck et al. 2003; Cotter et al. 2003). Near visual acuity (NVA) was measured using an Electronic Early Treatment Diabetic Retinopathy Study (ETDRS) test delivered on an Electronic Visual Acuity Tester system (to play on an iPod touch device (To et al. 2011; Gao et al. 2018b). Participants played the game wearing red/green glasses. All participants completed training on how to operate and play the game. At the start of each treatment session, participants aligned a nonius cross on the iPod screen and then commenced gameplay. The amblyopic eye saw the falling blocks and the fellow eye saw the static blocks that tessellated with the falling blocks. Lower rows of static blocks were presented to both eyes. Treatment began with fellow eye blocks presented at 20% contrast and amblyopic eye blocks at 100% contrast. Fellow eye contrast was increased each day following an automatic algorithm based on successful gameplay, and the game software recorded the contrast changes and duration of gameplay. Participants were instructed to play the game for 1 h everyday for 6 weeks. The training could be split across several sessions in the same day. The iPod was returned at the 6-week postrandomization visit.

The placebo group was identical to the active group except that it was not dichoptic (both eyes saw all game blocks at 100% contrast). Participants received the same instructions as the active group and wore red/green glasses during gameplay. Nonius cross alignment was the same in both the active and placebo game versions.

Figure 1 shows the CONSORT flow chart.

Results

DVA changes after optical treatment
Sixteen participants from both groups (seven in active and nine in placebo) were required to wear new prescription glasses. Distance visual acuity (DVA) for all participants was stable (visual acuity change was <0.10 logMAR) at the 4-week follow-up visit except for one participant (P4) who stabilized after 8 weeks of wearing optical correction. Distance visual acuity (DVA) improved significantly by 0.04 ± 0.05 logMAR in the amblyopic eye after optical treatment (t14 = 3.07, p < 0.05), while there was no significant change in the fellow eye (0.01 ± 0.05 log MAR; t15 = 0.56, p = 0.59).

Twenty-three participants were randomized to the active (n = 12) or placebo (n = 11) group. All participants could align the nonius cross on the iPod screen. There were no statistically significant differences in baseline age, patching history, optical correction history, DVA, NVA, Titmus stereo acuity, Randot stereo acuity or BCEA between the two groups (all p > 0.05). The baseline characteristics and the DVA of each participant are provided in Table 1.

Treatment adherence
The mean hours of gameplay within the 6-week treatment period were 37 ± 10 and 33 ± 10 hr for the active and placebo groups, respectively. There was no significant difference in treatment hours between the two groups; 10 out of 12 (83%) participants in the active group and 6 out of 11 (55%) in the placebo group reached 75% of the prescribed hours.

DVA changes after video game treatment (primary outcome)
After accounting for baseline amblyopic eye DVA, age, optical treatment history and patching history within the ANCOVA model, the adjusted mean change in amblyopic eye DVA from baseline to immediately after treatment was 0.09 log MAR (95% CI: 0.07–0.12) for the active group and 0.03 logMAR (95% CI: 0.00–0.06) for the placebo group. The difference between groups was statistically significant (F1,17 = 11.95, p = 0.003. nR2 = 0.41). Linear regression revealed no statistically significant association between improvement in amblyopic eye DVA and number of training hours (B = 0.00, p = 0.93), baseline amblyopic eye DVA (B = 0.01, p = 0.98), age (B = 0.00, p = 0.58), optical treatment history (B = 0.00, p = 0.45) or patching history (B = 0.00, p = 0.69) in the active group.
The change in amblyopic eye DVA from baseline remained significantly different between the two groups at the 12-week postrandomization visit (adjusted mean improvement: active group: 0.09 logMAR, 95% CI: 0.05 to 0.12; placebo group: 0.03 logMAR, 95% CI: -0.01 to 0.07; $F_{1,17} = 5.17$, $p = 0.04$, $\eta^2 = 0.23$). The difference between groups was not significant at the 24-week postrandomization visit (adjusted mean improvement: active group: 0.08 logMAR, 95% CI: 0.03 – 0.12; placebo: 0.05 logMAR, 95% CI: 0.01 to 0.09; $F_{1,17} = 0.99$, $p = 0.33$, $\eta^2 = 0.06$).

**Fixation stability**

The change in amblyopic eye BCEA immediately after treatment also did not differ significantly between the two groups (adjusted mean improvement: active group: -0.06 log deg$^2$, 95% CI: -0.18 to 0.06; placebo group: -0.02 log deg$^2$, 95% CI: -0.14 to 0.10; $F_{1,16} = 0.24$, $p = 0.63$, $\eta^2 = 0.01$).

**Stereo acuity**

There was a significant difference between groups in the change in Titmus stereo acuity immediately after treatment (adjusted mean improvement: active group: 0.40 log arcsec, 95% CI: 0.19–0.62; placebo group: 0.09 log arcsec, 95% CI: -0.13 to 0.32; $F_{1,16} = 4.39$, $p = 0.05$, $\eta^2 = 0.22$). Linear regression revealed no significant association between the change in Titmus stereo acuity and hours of gameplay ($B = 0.01$, $p = 0.52$), baseline Titmus stereo acuity ($B = -0.93$, $p = 0.09$), optical treatment history ($B = 0.03$, $p = 0.07$) or patching history ($B = 0.00$, $p = 0.07$) for the active group. There was a significant association between change in Titmus stereo acuity and age ($B = -0.03$, $p = 0.03$), whereby younger participants exhibited a greater improvement. The change in stereopsis from baseline remained significantly different between groups at the 12-week postrandomization visit (adjusted mean improvement: active group: 0.48 log arcsec, 95% CI: 0.29–0.66; placebo group: 0.17 log arcsec, 95% CI: -0.02 to 0.37; $F_{1,16} = 5.43$, $p = 0.03$, $\eta^2 = 0.25$) as well as at the 24-week postrandomization visit.

**Secondary outcomes after video game treatment**

**Near visual acuity**

The change in amblyopic eye NVA immediately after treatment did not differ significantly between groups (adjusted mean improvement: active group: 0.08 logMAR, 95% CI: 0.04–0.12; placebo group: 0.05 logMAR, 95% CI: 0.01 to 0.09; $F_{1,17} = 0.99$, $p = 0.33$, $\eta^2 = 0.06$).
| Participant | Active Age (years) | Gender (M/F) | Amblyopic eye (R/L) | Patching history (hr) | Optical correction history (years) | Amblyopia type | Given new optical correction | Amblyopic eye DVA before optical correction (log MAR) | Amblyopic eye DVA at randomization (log MAR) | Fellow eye DVA before optical correction (log MAR) | Fellow eye DVA at randomization (log MAR) |
|-------------|-------------------|--------------|--------------------|----------------------|-----------------------------------|----------------|-----------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|
| A1          | 22                | M            | R                  | 13                   | 140                              | Mixed          | N                           | 0.14                                          | n/a                                           | 0.22                                           | 0.22                                          |
| A2          | 46                | M            | L                  | 0                    | 38                               | Aniso          | Y                           | 0.16                                          | 0.20                                          | 0.22                                           | 0.28                                          |
| A3          | 41                | F            | R                  | 0                    | 13                               | Aniso          | Y                           | 0.28                                          | 0.24                                          | 0.22                                           | 0.26                                          |
| A4          | 40                | F            | L                  | 0                    | 6                                | Aniso          | Y                           | 0.20                                          | 0.18                                          | 0.22                                           | 0.22                                          |
| A5          | 30                | M            | L                  | 1440                 | 24                               | Aniso          | Y                           | 0.08                                          | 0.20                                          | 0.20                                           | 0.20                                          |
| A6          | 51                | M            | R                  | 0                    | 35                               | Aniso          | N                           | 0.22                                          | 0.14                                          | 0.22                                           | 0.22                                          |
| A7          | 9                 | F            | R                  | 90                   | 0.5                              | Aniso          | N                           | 0.22                                          | 0.22                                          | 0.22                                           | 0.22                                          |
| A8          | 8                 | M            | R                  | 180                  | 0.5                              | Aniso          | N                           | 0.28                                          | 0.28                                          | 0.28                                           | 0.16                                          |
| A9          | 26                | M            | R                  | 1080                 | 22                               | Aniso          | Y                           | 0.28                                          | 0.28                                          | 0.28                                           | 0.28                                          |
| A10         | 10                | F            | L                  | 720                  | 0                                | Mixed          | Y                           | 0.34                                          | 0.28                                          | 0.28                                           | 0.16                                          |
| A11         | 13                | M            | R                  | 1552                 | 11                               | Strabismic     | N                           | 0.24                                          | n/a                                           | n/a                                           | 0.00                                          |
| A12         | 11                | M            | L                  | 720                  | 4                                | Mixed          | 9/12 (58%)                  | 0.21 (0.06)                                   | n/a                                           | 0.12 (0.11)                                   |
| Mean (SD)   | 26 (16)           | 8M:4F        | 7R:5L              | 2744 (5465)           | 14 (13)                         | 2 mixed        | 1 strabismic                | 2 mixed                                       | 1 strabismic                                  | 2 mixed                                       | 1 strabismic                                  |
| P1          | 18                | F            | L                  | 1440                 | 12                               | Aniso          | Y                           | 0.14                                          | 0.16                                          | 0.22                                           | 0.22                                          |
| P2          | 27                | M            | L                  | 360                  | 23                               | Aniso          | Y                           | 0.16                                          | 0.12                                          | 0.22                                           | 0.22                                          |
| P3          | 29                | F            | L                  | 360                  | 21                               | Aniso          | Y                           | 0.28                                          | 0.24                                          | 0.04                                           | 0.00                                          |
| P4          | 9                 | F            | R                  | 1080                 | 2                                | Aniso          | Y                           | 0.32, after 4 weeks: 0.16                       | After 8 weeks: 0.16                           | 0.08, after 4 weeks: 0.16                       | After 8 weeks: 0.10                           |
| P5          | 37                | M            | R                  | 0                    | 21                               | Aniso          | Y                           | 0.12, after 4 weeks: 0.16                       | After 8 weeks: 0.16                           | 0.06, after 4 weeks: 0.16                       | After 8 weeks: 0.10                           |
| P6          | 24                | M            | L                  | 2160                 | 20                               | Aniso          | Y                           | 0.24, after 4 weeks: 0.16                       | After 8 weeks: 0.16                           | 0.24                                           | 0.24, after 4 weeks: 0.16                       |
| P7          | 31                | F            | L                  | 720                  | 25                               | Aniso          | Y                           | 0.20, after 4 weeks: 0.16                       | After 8 weeks: 0.16                           | 0.16                                           | 0.16, after 4 weeks: 0.16                       |
| P8          | 14                | M            | L                  | 1440                 | 11                               | Mixed          | N                           | 0.18                                          | 0.26                                          | 0.22                                           | 0.22                                          |
| P9          | 43                | F            | L                  | 720                  | 0                                | Aniso          | N                           | 0.28                                          | 0.22                                          | 0.04                                           | 0.04                                          |
| P10         | 27                | M            | L                  | 360                  | 23                               | Strabismic     | Y                           | 0.28, after 4 weeks: 0.16                       | After 8 weeks: 0.16                           | 0.22                                           | 0.04, after 4 weeks: 0.16                       |
| P11         | 31                | M            | L                  | 360                  | 21                               | Aniso          | Y                           | 0.26, after 4 weeks: 0.16                       | After 8 weeks: 0.16                           | 0.18                                           | 0.04, after 4 weeks: 0.16                       |
| Mean (SD)   | 26 (10)           | 6M:5F        | 2R:9L              | 1996 (4159)           | 16 (9)                          | 1 strabismic   | 9/11 (82%)                  | 0.18 (0.06)                                   | n/a                                           | 0.09 (0.09)                                   | 0.18 (0.06)                                   |
adjusted mean improvement: active group: 0.46 log arcsec, 95% CI: 0.27–0.65; placebo group: 0.18 log arcsec, 95% CI: −0.01 to 0.38; \( F_{1,16} = 4.42, p = 0.05, \eta^2 = 0.22 \). These results indicated a significant improvement in Titmus stereo acuity that lasted 18 weeks after cessation of active treatment. Figure 3 shows the Titmus stereo acuity of the participants in the two groups at the four visits.

There was also significant difference between groups in Randot Preschool Stereo Acuity change immediately after treatment (active group: 0.23 log arcsec, 95% CI: 0.00–0.46; placebo group: −0.10 log arcsec, 95% CI: −0.34 to 0.14; \( F_{1,16} = 4.42, p = 0.05, \eta^2 = 0.22 \)). However, the treatment effect was not present at the week 12 (active group: 0.10 log arcsec, 95% CI: −0.12 to 0.31; placebo group: −0.04 log arcsec, 95% CI: −0.26 to 0.18; \( F_{1,16} = 0.38, p = 0.59, \eta^2 = 0.05 \) and the week 24 visits (active group: 0.10 log arcsec, 95% CI: −0.28 to 0.47; placebo group: −0.30 log arcsec, 95% CI: −0.70 to 0.10; \( F_{1,16} = 2.23, p = 0.16, \eta^2 = 0.12 \)).

Fellow eye
There were no significant between-group differences immediately after treatment for change in fellow eye DVA (adjusted mean improvement: active group: 0.01 logMAR, 95% CI: −0.02 to 0.04; placebo group: 0.02 logMAR, 95% CI: −0.01 to 0.05; \( F_{1,16} = 0.18, p = 0.68, \eta^2 = 0.01 \), fellow eye NVA (adjusted mean improvement: active group: 0.02 logMAR, 95% CI: −0.01 to 0.05; placebo group: 0.01 logMAR, 95% CI: −0.02 to 0.04; \( F_{1,16} = 0.41, p = 0.53, \eta^2 = 0.02 \)) or fellow eye BCEA (adjusted mean improvement: active group: −0.06, 95% CI: −0.19 to 0.08; placebo group: −0.05, 95% CI: −0.20 to 0.09; \( F_{1,16} = 0.00, p = 0.99, \eta^2 = 0.00 \)).

The outcome measurements for each participant at each different visit are provided in Table 2.

Change in interocular contrast
In the active group, 10 out of the 12 participants reached 100% fellow eye contrast at the end of treatment, and one participant achieved 93% (Fig. 4). One participant’s iPod log file (A10) was not stored due to a technical error during weeks 4–6, and we treated this as missing data. The contrast of the images between the two eyes was equal throughout the whole training period in the placebo group, and therefore, change in fellow eye contrast was irrelevant.

Adverse effects
No diplopia or discomfort was reported. Two participants reported mild adaptation difficulty during the initial phase of optical treatment.

Discussion
It is worth asking the question, ‘why treat mild cases of amblyopia?’ Firstly, they are particularly difficult to treat.
Table 2. Outcome measurements of each participant.

| Participant | Amblyopic eye DVA (log MAR) | Amblyopic eye NVA (log MAR) | Titmus stereo acuity (log arcsec) | Randot preschool (log arcsec) | Amblyopic eye BCEO (log deg²) |
|-------------|-----------------------------|-----------------------------|----------------------------------|-------------------------------|-------------------------------|
|             | A = active                  | P = placebo                 |                                  |                               |                               |
| A1          | 25  | 0.14 | 0.10  | 0.08  | 0.10  | 0.36  | 0.20  | 0.14  | 0.18  | 2.20  | 2.20  | 1.80  | 1.80  | 4.00  | 4.00  | 4.00  | 4.00  | 2.37  | 0.21  | 0.12  | 0.18  | 1.20  | 1.80  | 1.80  | 4.00  | 4.00  | 4.00  | 0.18  |
| A2          | 43  | 0.20 | 0.12  | 0.16  | 0.04  | 0.42  | 0.36  | 0.40  | 0.42  | 2.20  | 1.30  | 1.30  | 1.51  | 2.60  | 2.00  | 2.60  | 2.30  | 0.11  | 0.10  | 0.35  | 0.10  |
| A3          | 36  | 0.24 | 0.22  | 0.16  | 0.20  | 0.66  | 0.44  | 0.72  | 0.52  | 2.30  | 2.60  | 2.20  | 2.20  | 4.00  | 2.90  | 4.00  | 4.00  | 0.03  | 0.33  | 0.11  | 0.06  |
| A4          | 40  | 0.18 | 0.08  | 0.10  | 0.12  | 0.32  | 0.32  | 0.38  | 0.38  | 1.80  | 1.51  | 1.30  | 1.40  | 2.00  | 2.00  | 2.00  | 2.00  | 0.00  | 0.21  | 0.18  | 0.17  |
| A5          | 13  | 0.10 | 0.04  | 0.00  | 0.00  | 0.20  | 0.16  | 0.10  | 0.12  | 2.00  | 1.60  | 1.40  | 1.40  | 2.00  | 2.00  | 2.00  | 1.60  | -0.55 | -0.70 | -0.64 | -0.28 |
| A6          | 48  | 0.22 | 0.10  | 0.08  | 0.10  | 0.72  | 0.60  | 0.30  | 0.30  | 2.00  | 1.80  | 1.40  | 1.60  | 2.60  | 2.60  | 2.30  | 2.30  | -0.05 | 0.10  | 0.19  | 0.02  |
| A7          | 32  | 0.22 | 0.16  | 0.22  | 0.26  | 0.26  | 0.22  | 0.32  | 0.38  | 2.30  | 1.60  | 1.60  | 1.40  | 2.30  | 1.78  | 1.78  | 1.78  | -0.15 | -0.03 | -0.17 | -0.04 |
| A8          | 43  | 0.20 | 0.08  | 0.06  | 0.10  | 0.22  | 0.12  | 0.12  | 0.22  | 2.00  | 1.40  | 1.30  | 1.40  | 2.00  | 1.78  | 1.60  | 2.00  | 0.50  | 0.58  | 0.51  | 0.19  |
| A9          | 48  | 0.14 | 0.02  | 0.00  | 0.04  | 0.12  | 0.04  | 0.10  | 0.14  | 2.15  | 1.51  | 1.50  | 1.60  | 2.90  | 2.90  | 2.90  | 4.00  | -0.60 | -0.40 | -0.68 | -0.80 |
| A10         | 41  | 0.28 | 0.24  | 0.28  | 0.30  | 0.44  | 0.34  | 0.40  | 0.44  | 2.20  | 1.30  | 2.20  | 2.20  | 4.00  | 4.00  | 4.00  | 4.00  | 0.13  | 0.14  | 0.08  | 0.09  |
| A11         | 36  | 0.28 | 0.14  | 0.18  | 0.18  | 0.40  | 0.26  | 0.30  | 0.30  | 1.70  | 1.30  | 1.30  | 1.51  | 4.00  | 4.00  | 4.00  | 4.00  | 0.02  | 0.33  | 0.14  | 0.15  |
| A12         | 42  | 0.24 | 0.18  | 0.20  | 0.18  | 0.50  | 0.46  | 0.52  | 0.54  | 2.60  | 2.60  | 2.60  | 2.60  | 4.00  | 4.00  | 4.00  | 4.00  | 0.40  | 0.54  | 0.93  | 0.04  |
| Mean (SD)   | 37 (10) | 0.21 | 0.12  | 0.13  | 0.13  | 0.39  | 0.29  | 0.32  | 0.33  | 2.13  | 1.73  | 1.67  | 1.68  | 3.03  | 2.83  | 2.93  | 3.00  | -0.07 | -0.02 | -0.02 | -0.14 |

BCEO = bivariate contour ellipse area; DVA = distance visual acuity, NVA = near visual acuity.
vance, the restoration of binocular vision is an important and significant achievement.

We observed a significant improvement in amblyopic eye DVA and stereo acuity (both Titmus and Randot stereo acuities) following active binocular treatment compared to a placebo treatment in our mild amblyopia participants. As this is the first study reporting the treatment effect of binocular treatment in mild amblyopia, we cannot compare our results directly with prior studies, all of which have focused on moderate-to-severe amblyopia (To et al. 2011; Hess et al. 2012; Birch et al. 2015; Vedamurthy et al. 2015; Holmes et al. 2016; Kelly et al. 2016; Manh et al. 2018; Gao et al. 2018b; PEDIG et al. 2019). That being said, it is notable that the treatment adherence we observed (83% of active group participants reached 75% of the prescribed treatment hours) is substantially higher than many previous binocular treatment studies, including those that found no treatment effect in moderate-to-severe amblyopia (Manh et al. 2018; Gao et al. 2018b; PEDIG et al. 2019). However, we did not observe a dose–response relationship for the active group. This may have been due to our small sample size, and the treatment hours in our participants were skewed towards good adherence. In addition, it is currently impossible to precisely define treatment dose for binocular treatment in the home environment because the frequency and duration of gazes away from the treatment device screen are not recorded. The distribution of gameplay throughout the day (one long session versus many short sessions) is also not accounted for.

Therefore, duration of gameplay as recorded by the treatment device may be only a crude estimate of dose. The development or more sophisticated adherence monitoring systems or supervised in-office studies are required to directly address the issue of dose-response for binocular treatment.

Although there was not a statistically significant between-group difference in absolute number of hours played, a smaller percentage of participants in the placebo group (55%) than the active group (83%) completed 75% of the prescribed dose (31.5 hr completed from 42 hr prescribed). As shown in Table 2, two participants from the placebo group failed to meet the 75% threshold by only 1.5 hr. If these participants had played an extra 1.5 hr, the placebo group percentage of participants who completed 75% of the prescribed treatment dose would have increased to 72%, a closer match to the active group. In a much larger sample of participants with moderate-to-severe amblyopia, Gao and colleagues found no significant differences in adherence between active and placebo binocular treatment groups (Gao et al. 2018b).

We found that the significant between-treatment-group difference in amblyopic eye DVA was no longer present at the 24-week postrandomization follow-up. With reference to Fig. 2, we speculate that this effect was not due to a regression effect in the active group, but rather a gradual improvement in the placebo group. There were more participants who required new optical prescription in the placebo (82%, nine out of 11) than the active (58%, seven out of 12) group before the randomization. Hence, it is possible that the placebo group exhibited a greater, gradual optical treatment effect (Stewart et al. 2004; PEDIG et al. 2005; PEDIG et al. 2006; PEDIG et al. 2012; Gao et al. 2018a) than the active group that was not controlled for by our stability criteria of <0.10 logMAR change over 4 weeks.

**Fixation stability**

We did not find any effect of binocular treatment on fixation stability. However, our sample of participants with mild amblyopia did not exhibit reduced amblyopic eye fixation stability (BCEA values did not differ between the fellow

---

**Fig. 4.** Change of image contrast in the iPod game in the fellow eye in the active group.
and amblyopic eyes) at the baseline. This observation (reasonable fixation stability in mild amblyopic eye) is in general agreement with previous reports, indicating that poorer fixation stability is correlated with poorer visual acuity level in amblyopia (Subramanian et al. 2013; Raveendran et al. 2019). Our visual acuity inclusion criteria may not have allowed us to capture individuals with fixation stability impairments.

**Stereo acuity**

We observed a significant improvement in stereo acuity measured by the two stereo tests immediately after the 6-week binocular treatment in the active group. However, only the improvement on the Titmus stereo test lasted up to 18 weeks post-treatment. The Titmus stereo test measures local stereopsis, whereas the Randot preschool stereo test measure global stereopsis (Fawcett & Birch 2003). In addition, the Titmus stereo test has potential monocular cues whereas the Randot test does not. These differences between the tests may underlie the different treatment outcomes.

**Limitation of this study**

The sample size for this pilot study was much smaller than that of recent randomized clinical trials. In addition, our results suggest that stricter DVA stability criteria and a longer optical treatment period are required for participants with mild amblyopia as visual acuity improvements may be particularly gradual in this group. However, despite these limitations, we did observe positive treatment effects within a placebo-controlled design. Our results stand alone and may also serve to power a more substantial randomized controlled trial study designed to test treatments for mild amblyopia. An additional limitation is that the clinician conducting the outcome measures was not masked to participants’ treatment group allocation. This was due to resource limitations and introduced a source of bias.

**Conclusion**

Home-based dichoptic video gameplay may be an effective method to improve amblyopic eye DVA and stereo acuity in mild amblyopia.

**References**

Ageri P, Kugelberg U, Kugelberg, M & Zetterstrom, C. (2013): Two-year follow-up of a randomized trial of spectacles plus alternate-day patching to treat strabismic amblyopia. Acta Ophthalmol 91: 678–684.

Beck RW, Moke PS, Turpin AH. (2003): A computerized method of visual acuity testing: adaptation of the early treatment of diabetic retinopathy study testing protocol. Am J Ophthalmol 135: 194–205.

Birch EE, Li SL, Jost RM, Morales, SE, De La Cruz, A, Stager, D Jr, Dao, L & Stager, DR Sr. (2015): Binocular iPad treatment for amblyopia in preschool children. J APPOS 19: 6–11.

Chen PL, Chen JT, Tai MC, Fu, JJ, Chang, CC & Lu, DW. (2007): Anisometropic amblyopia treated with spectacle correction alone: possible factors predicting success and time to start patching. Am J Ophthalmol 143: 54–60.

Chung ST, Kumar G, Li RW & Levi, DM. (2015): Characteristics of fixational eye movements in amblyopia: Limitations on fixation stability and acuity? Vision Res 114: 87–99.

Cuijfreeda JK, Kenyon RV & Stark L (1979): Fixational eye movements in amblyopia and strabismus. J Am Optom Assoc 50: 1251–1258.

Cotter SA, Chu RH, Chandler DL et al. (2003): Reliability of the electronic early treatment diabetic retinopathy study testing protocol in children 7 to <13 years old. Am J Ophthalmol 136: 655–661.

Pediatric Eye Disease Investigator Group, Cotter, SA & Edwards, AR. (2006): Treatment of anisometropic amblyopia in children with refractive correction. Ophthalmology 113: 895–903.

Fawcett SL & Birch EE (2003): Validity of the Titmus and Randot circles tasks in children with known binocular vision disorders. J APPOS 7: 333–338.

Gao TY, Anstice N, Babu RJ et al. (2018a): Optical treatment of amblyopia in older children and adults is essential prior to enrolment in a clinical trial. Ophthalmic Physiol Opt 38: 129–143.

Gao TY, Guo CX, Babu RJ et al. (2018b): Effectiveness of a binocular video game vs placebo video game for improving visual functions in older children, teenagers, and adults with amblyopia: a Randomized Clinical Trial. JAMA Ophthalmol 136: 172–181.

Gonzalez EG, Wong AM, Niechwiej-Szwedo E, Tarrita-Nistor, L & Steinbach, MJ. (2012): Eye position stability in amblyopia and in normal binocular vision. Invest Ophthalmol Vis Sci 53: 5386–5394.

Guo CX, Babu RJ, Black JM et al. (2016): Binocular treatment of amblyopia using videogames (BRAVO): study protocol for a randomised controlled trial. Trials 17: 504.

Herbison N, MacKeith D, Vivian A et al. (2016): Randomised controlled trial of video clips and interactive games to improve vision in children with amblyopia using the 1-BiT system. Br J Ophthalmol 100: 1511–1516.

Hess RF & Thompson B (2015a): Amblyopia and the binocular approach to its therapy. Vision Res 114: 4–16.

Hess RF, Mansouri B & Thompson B (2010): A new binocular approach to the treatment of amblyopia in adults well beyond the critical period of visual development. Restor Neurol Neurosci 28: 793–802.

Hess RF, Mansouri B & Thompson B (2011): Restoration of binocular vision in amblyopia. Strabismus 19: 110–118.

Hess RF, Thompson B, Black JM, Machara, G, Zhang, P, Bobier, WR & Cooperstock, J. (2012): An iPod treatment of amblyopia: an updated binocular approach. Optometry 83: 87–94.

Hess RF, Babu RJ, Clavagnier S, Black, J, Bobier, W & Thompson, B. (2014): The iPod binocular home-based treatment for amblyopia in adults: efficacy and compliance. Clin Exp Optom 97: 389–398.

Holmes JM (2018): Lessons from recent randomized clinical trials of binocular treatment for amblyopia. JAMA Ophthalmol 136: 181–183.

Holmes JM, Melia M, Bradfield YS, Cruz, OA, Forbes, B & Pediatric Eye Disease Investigator Group. (2007): Factors associated with recurrence of amblyopia on cessation of patching. Ophthalmology 114: 1427–1432.

Holmes JM, Manh VM, Lazar EL et al. (2016): Effect of a binocular iPad game vs part-time patching in children aged 5 to 12 years with amblyopia: a randomized clinical trial. JAMA Ophthalmol 134: 1391–1400.

Kelly KR, Jost RM, Dao L, Beauchamp, CL, Leffler, JN & Birch, EE. (2016): Binocular iPad game vs patching for treatment of amblyopia in children: a randomized clinical trial. JAMA Ophthalmol 134: 1402–1408.

Knox PJ, Simmers AJ, Gray LS & Cleary, M. (2012): An exploratory study: prolonged periods of binocular stimulation can provide an effective treatment for childhood amblyopia. Invest Ophthalmol Vis Sci 53: 817–824.

Levi DM & Li RW (2009): Perceptual learning as a potential treatment for amblyopia: a mini-review. Vision Res 49: 2535–2549.

Li J, Hess RF, Chan LY, Deng, D, Yang, X, Chen, X, Yu, M & Thompson, B. (2013a): Quantitative measurement of interocular suppression in anisometropic amblyopia: a case-control study. Ophthalmology 120: 1672–1680.

Li J, Thompson B, Deng D, Chan, LY, Yu, M & Hess, RF. (2013b): Dichoptic training enables the adult amblyopic brain to learn. Curr Biol 23: R308–R309.

Li SL, Jost RM, Morales SE, De La Cruz, A, Dao, L, Stager, D Jr & Birch, EE. (2015): Binocular iPad treatment of amblyopia for lasting improvement of visual acuity. JAMA Ophthalmol 133: 479–480.

Manh VM, Holmes JM, Lazar EL et al. (2018): A randomized trial of a binocular iPad game versus part-time patching in
children aged 13 to 16 years with amblyopia. Am J Ophthalmol 186: 104–115.

Pediatric Eye Disease Investigator Group, Repka, MX & Beck, RW. (2003): A randomized trial of patching regimens for treatment of moderate amblyopia in children. Arch Ophthalmol 121: 603–611.

Pediatric Eye Disease Investigator Group, Scheiman, MM & Hertle, RW. (2005): Randomized trial of treatment of amblyopia in children aged 7 to 17 years. Arch Ophthalmol 123: 437–447.

Pediatric Eye Disease Investigator Group, Repka, MX & Beck, RW. (2003): A randomized trial of patching regimens for treatment of moderate amblyopia in children. Arch Ophthalmol 121: 603–611.

Pediatric Eye Disease Investigator Group, Scheiman, MM & Hertle, RW. (2005): Randomized trial of treatment of amblyopia in children aged 7 to 17 years. Arch Ophthalmol 123: 437–447.

Pediatric Eye Disease Investigator Group, Cotter, SA & Foster, NC. (2012): Optical treatment of strabismic and combined strabismic-anisometropic amblyopia. Ophthalmology 119: 150–158.

Pediatric Eye Disease Investigator Group, Valence, DK & Lazar, EL. (2015): A randomized trial of adding a plano lens to atropine for amblyopia. J AAPOS 19: 42–48.

Raveendran RN, Babu RJ, Hess RF & Bobier, WR. (2014): Transient improvements in fixational stability in strabismic amblyopes following bifoveal fixation and reduced interocular suppression. Ophthalmic Physiol Opt 34: 214–225.

Raveendran RN, Bobier W & Thompson B (2019): Reduced amblyopic eye fixation stability cannot be simulated using retinal-defocus-induced reductions in visual acuity. Vision Res 154: 14–20.

Rouse MW, Cooper JS & Cotter SA (1994): Optometric clinical practice guideline - Care of the patient with amblyopia. American Optometric Association. Available at: http://www.aoa.org/documents/optometrists/CPG-4.pdf (Accessed on 15 Jan 2020).

Stewart CE, Moseley MJ, Fielder AR, Stephens, DA & the MOTAS cooperative. (2004): Refractive adaptation in amblyopia: quantification of effect and implications for practice. Br J Ophthalmol 88: 1552–1556.

Su L, Yan H, Xing Y, Zhang, Y & Zhu, B. (2016): Evaluation of occlusion treatment outcomes for unilateral amblyopia using different definitions of outcome. Semin Ophthalmol 31: 249–255.

Subramanian V, Jost RM & Birch EE (2013): A quantitative study of fixation stability in amblyopia. Invest Ophthalmol Vis Sci 54: 1998–2003.

Tang EW, Li BC, Yeung IY & Li, KK. (2014): Occlusion therapy in amblyopia: an experience from Hong Kong. Hong Kong Med J 20: 32–36.

Thompson B (2019): Binocular treatment of amblyopia: from the laboratory to clinical trials. Annals. Eye Sci 4: 14.

To L, Thompson B, Blum JR, Maehara, G, Hess, RF & Cooperstock, JR. (2011): A game platform for treatment of amblyopia. IEEE trans Neural Sys Rehab Eng 19: 280–289.

Tsirlin I, Colpa L, Goltz HC & Wong, AM. (2015): Behavioral training as new treatment for adult amblyopia: a meta-analysis and systematic review. Invest Ophthalmol Vis Sci 56: 4061–4075.

Vedamurthy I, Nahum M, Huang SJ, Zheng, F, Bayliss, J, Bavelier, D & Levi, DM. (2015): A dichoptic custom-made action video game as a treatment for adult amblyopia. Vision Res 114: 173–187.

Vedamurthy I, Knill DC, Huang SJ, Yung, A, Ding, J, Kwon, OS, Bavelier, D & Levi, DM. (2016): Recovering stereo vision by squashing virtual bugs in a virtual reality environment. Philos Trans R Soc Lond B Biol Sci 371: 20150264.

Webber AL, Wood JM & Thompson B (2016): Fine motor skills of children with amblyopia improve following binocular treatment. Invest Ophthalmol Vis Sci 57: 4713–4720.

Received on February 27th, 2020. Accepted on July 25th, 2020.

Correspondence:
Carly S. Y. Lam
School of Optometry
The Hong Kong Polytechnic University
Hung Hom, Kowloon
Hong Kong
Tel: +852 27666091
Fax: +852 27646051
Email: carly.lam@polyu.edu.hk

The BRAVO study Hong Kong site team provided vital logistical and technical assistance. We also thank Dr Paul Lee who provided valuable statistical advice. This study was supported by the Health and Medical Research Fund of Hong Kong (Ref 11122991, acct no. K-ZC01) and ZVPK. Authors RFH and BT are inventors on two patents relating to binocular treatment.